If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() Chemical Biology & Drug DesignVolume 71 Issue 5, Pages 494 - 500 Published Online: 25 Mar 2008 © 2010 John Wiley & Sons A/S
Abstract | References | Full Text: HTML, PDF (Size: 292K) | Supporting Information | Related Articles | Citation Tracking Research Letter Synthetic Mimetics of the gp130 Binding Site for Viral Interleukin-6 as Inhibitors of the vIL-6–gp130 Interaction Copyright Journal compilation © 2008 Blackwell Munksgaard KEYWORDS binding site • gp130 • interleukin-6 • mimicry • peptide • protein–ligand interactions ABSTRACTThe transmembrane protein gp130 acts as the signal transducing receptor subunit for interleukin-6 type cytokines, including viral interleukin-6, which is encoded by the Kaposi's sarcoma-associated herpes virus. Viral interleukin-6 has been shown to mimic human IL-6 functions, including activation of the JAK1 and STAT1/3 signaling pathways. Based on the crystal structure of three extracellular domains of gp130 in complex with viral interleukin-6, we have designed and synthesized a range of assembled peptides that mimic the sequentially discontinuous binding site of gp130 for viral interleukin-6. These peptides, which present the three binding site fragments of gp130 in a nonlinear, discontinuous fashion, were shown to inhibit the interaction of gp130 with viral interleukin-6, as well as the stimulation of viral interleukin-6-induced cell proliferation. These results validate the concept of synthetic mimicry of discontinuous protein-binding sites through assembled peptides, and the use of such molecules as modulators of protein–ligand interactions. Received 17 January 2008, revised 23 February 2008 and accepted for publication 24 February 2008 |